Drug-Eluting stents as an alternative to traditional stenting in the treatment of Coronary Artery Disease (Cypher stent)

Please note: All assessments are current as of the review date; however, new evidence that may have been published subsequently is not considered.
Review Date:	June 11, 2003
Recommendation:	This topic was reviewed on June 11, 2003. It was determined that: Sirolimus-eluting stents for patients with angina pectoris or silent ischemia and greater than 50 percent de novo stenosis of ≤30 mm in length, of one or more native coronary arteries with a diameter ≥2.5 mm to ≤3.5 mm meet technology assessment criteria. Sirolimus-eluting stents for the treatment of stenotic lesions of the left main coronary artery; for the treatment of stenotic lesions of non-coronary arteries such as saphenous vein grafts, for in-stent restenosis, for treatment of non-atherosclerotic anatomies (i.e. thrombotic lesions associated with acute MI), for bifurcation lesions, or prior brachytherapy, and other drug-eluting stents do not meet technology assessment criteria.
Decision:	Partially Meets CTAF Criteria
Full Assessment:	Download (PDF)

Search Assessments